Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Comment
Editorial

The Guardian view on weight-loss jabs and addiction: there is too much moralising about these remarkable medicines

Boxes of Novo Nordisk's weight-loss drug Wegovy.
‘One in eight Americans have taken a GLP-1 drug, and about one in 20 in the UK.’ Photograph: Reuters

In the years since so-called weight-loss jabs entered widespread use, there have been reports that these drugs may not just reduce food cravings, but in fact cravings and desires full-stop. Earlier this month, a study using large-scale data from US veterans undergoing diabetes treatment suggested that those on the jabs were less likely to develop addictions to a wide range of drugs. Patients already using substances appeared about half as likely to suffer overdose or drug-related death if they were taking the jab as well.

This is an exciting avenue for future research. These medicines work partly on satiation and reward centres in the brain. It is likely that problematic food and drug cravings share a similar biological basis, and next-generation medicines may be more powerful or more targeted to one or the other. But, in the meantime, we should expect that existing weight-loss drugs will end up recommended (or prescribed off-label) for addiction treatment. This should make us rethink our approach to these remarkable medicines.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.